Westphal S, Hansson S, Mjörnstedt L, Mölne J, Swerkersson S, Friman S
Department of Pediatrics, The Queen Silvia Children's Hospital, Göteborg, Sweden.
Transplant Proc. 2006 Oct;38(8):2659-60. doi: 10.1016/j.transproceed.2006.07.034.
In contrast to focal segmental glomerulosclerosis, which is well known to recur early in a renal graft, there are only few cases described with recurrence of immunoglobulin M (IgM) nephropathy after transplantation. We herein describe a patient with early recurrence of IgM nephropathy. A 15-year-old boy with nephrotic syndrome (IgM nephropathy) proceeding to end-stage renal disease was on dialysis before living related renal transplantation. Native kidneys were not removed. Standard immunosuppression including steroids, tacrolimus, and mycophenolate mofetil yielded initially good graft function with the s-creatinine falling to 73 micromol/L. Proteinuria was present on day 1, increasing to 20 g/L after 3 days. S-creatinine increased to 158 micromol/L and urine production diminished. A graft biopsy showed no rejection or glomerulopathy but protein vacuoles were seen within tubular cells indicating massive proteinuria. Treatment with plasma exchanges, immunoglobulin, and steroids was started. Hemodialysis was necessary. Proteinuria improved to 3.5 g/L, but s-creatinine continued to rise and a second graft biopsy showed vascular rejection (Banff type IIA). The patient was treated with antithymocyte globulin and further plasma exchanges. A single dose of rituximab was given. Five months after transplantation the s-creatinine was 67 micromol/L and there was no proteinuria. In this case early recurrence of nephrotic syndrome occurred on the first posttransplant day in combination with later occurring vascular rejection. Successful treatment included a combination of plasma exchanges, rituximab, immunoglobulin, and antithymocyte globulin.
与局灶节段性肾小球硬化症不同,后者在肾移植早期复发是众所周知的,而移植后免疫球蛋白M(IgM)肾病复发的病例仅有少数报道。我们在此描述一例IgM肾病早期复发的患者。一名15岁患有肾病综合征(IgM肾病)并进展至终末期肾病的男孩,在进行亲属活体肾移植前接受透析治疗。未切除自体肾。包括类固醇、他克莫司和霉酚酸酯在内的标准免疫抑制治疗最初使移植肾功能良好,血清肌酐降至73微摩尔/升。术后第1天出现蛋白尿,3天后增至20克/升。血清肌酐升至158微摩尔/升,尿量减少。移植肾活检未发现排斥反应或肾小球病变,但在肾小管细胞内可见蛋白空泡,提示大量蛋白尿。开始采用血浆置换、免疫球蛋白和类固醇治疗。需要进行血液透析。蛋白尿改善至3.5克/升,但血清肌酐继续升高,第二次移植肾活检显示血管排斥反应(班夫IIA型)。患者接受抗胸腺细胞球蛋白治疗并进一步进行血浆置换。给予单剂量利妥昔单抗。移植后5个月,血清肌酐为67微摩尔/升,无蛋白尿。在该病例中,肾病综合征在移植后第1天早期复发,并伴有后期出现的血管排斥反应。成功的治疗包括血浆置换、利妥昔单抗、免疫球蛋白和抗胸腺细胞球蛋白联合应用。